Autocrine Activity of Engineered IL-33 mRNA Enhances Adoptive T Cell Therapy for Peritoneal Carcinomatosis and Synergizes with IL-12 mRNA

Adoptive cell therapy (ACT) using tumor-specific T cells has emerged as a promising strategy; however, its efficacy is often hindered by the immunosuppressive tumor microenvironment (TME). Interleukin-33 (IL-33), a member of the IL-1 family, plays a dual role in immunity and inflammation, with the potential to enhance antitumor responses.

Here, we investigated the impact of IL-33 mRNA-engineered T cells on ACT efficacy in murine models of PC and explored the potential synergy with IL-12 mRNA.